Article
T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA.
All News
Article
There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there are no current licensed therapies.
Dr. Antoni Chan
Tweet
EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ
Dr. Antoni Chan
Tweet
The course of symptoms in CSA to RA showed greater severity in the ACPA+ group compared to the ACPA- group. This correlated with MRI-subclinical joint score, suggesting different underlying processes Khidir S Abst#POS319 #EULAR2023 @RheumNow https://t.co/C2ADAkkSM2
Dr. John Cush
Tweet
Better at Predicting RA from MRI: Humans or Computers?
https://t.co/xRVatfiRKS https://t.co/Gwypq8lcdl
Dr. John Cush
Tweet
The future of lupus treatment is oral therapies?
There has been an explosion of trials in SLE, including nonrenal and glomerulonephritis studies.
@Janetbirdope
https://t.co/IQ9bxbTSV4 https://t.co/jVYOphxpAE
Dr. Antoni Chan
Tweet
In an early SpA (DESIR) cohort, the occurrence of a first pregnancy did not seem to increase the number of imaging abnormalities of the SIJ. Overall no significant changes in radiographic and MRI imaging abnormalities of the SIJ, Molto A, Abst#POS0303, #EULAR2023 @RheumNow
Aurelie Najm
Tweet
Supervised 12 weeks High-intensity interval training program
Improves Vo2 peak in IA patients
But does not improve pain or fatigue
It is disappointing but it is also a small study w/ n=30 pts in each group.
It is unclear if the type of exercise has an impact on outcome https://t.co/Plk7sflrh5
Aurelie Najm
Tweet
What happens when an AI-based symptom checker & an online self-referral tool play Rheumatologists?
They don't seem to do great yet!
600 new pts, outw/ 36% dvlpd IA
IA Sens 62% Spe 47%
Tool Sens 66% Spe 54%
More work needed to implement these in practice
#EULAR23 @Rheumnow
Dr. John Cush
Tweet
RheumNow’s expanded coverage of the #EULAR2023 meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
Dr. John Cush
Tweet
RheumNow Eular 2023 Daily Recap Series https://t.co/ZJd3mSBcau
Dr. John Cush
Tweet
AOSD: Young vs. Elderly Onset
AOSDis an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million.
https://t.co/PPI1fvwLAf https://t.co/qMXMsbpwl3
Alina DIMA
Tweet
Top Influencers of #EULAR2023 👉 @eular_org @EMEUNET @RheumNow @ARD_BMJ @drdavidliew @Janetbirdope https://t.co/uUJM6tW824 via @symplur
David Liew
Tweet
Wasn’t following the SLE stuff #EULAR2023 but heard a lot of talk about both telitacicept & CAR-T, including meeting highlights by Christian Dejaco.
Both look pretty exciting - the longer the sustained remission with CAR-T, the more it looks like maybe the real deal @RheumNow https://t.co/oKzb8ojTcz
Md Yuzaiful Md Yusof
Tweet
#EULAR2023 Clinical Highlights. Osteoarthritis. OP0071 Single centre Phase 2 RCT showed Denosumab halted erosion in Erosive OA at 24 weeks treatment, and the treatment effect enhances after 48 weeks vs PBO @RheumNow https://t.co/YWFUg3cp7P
Dr. John Cush
Tweet
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on YouTube, Twitter and LinkedIn. https://t.co/i8rm5t8mFS
Dr. John Cush
Tweet
RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
Bella Mehta
Tweet
Depositions of crystals in coronary arteries were associated with MACE @rheumnow #EULAR2023 https://t.co/VHxtsB7ZsA
Aurelie Najm
Tweet
Adherence to TNFi follows different trajectories
Cluster 1: “moderate then high” 51%
Cluster 2: “moderate then low” 20%
Cluster 3: “low adherence, to discontinuation” 18%
Cluster 4: “low then high adherence” 11%
Most demographic & clinical features CAN NOT predict trajectory! https://t.co/4wLg6b70Kl
David Liew
Tweet
@eular_org recommendations session #EULAR2023 - and the first recommendation is one I’m so glad is up front:
Adult Onset Still’s Disease (AOSD) and Systemic JIA (sJIA) are the same disease.
If anything, it’s the really young sJIA (<18 months old) which is different @RheumNow https://t.co/OCDeeNtNoR
